Biopharma CRISPR Gene Therapies sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Biopharma CRISPR Gene Therapies
1.1 - About Biopharma CRISPR Gene Therapies sector
Companies in Biopharma CRISPR Gene Therapies engineer and advance CRISPR-based drugs for in vivo and ex vivo treatment of genetic disease and cancer. They combine proprietary editing systems, targeted delivery, and clinical development to create durable, potentially curative interventions. Their value lies in validated editing platforms, scalable manufacturing, and regulatory know‑how that move candidates from discovery into pivotal trials while enabling pharma partnerships and indication expansion.
These companies typically run in vivo gene editing programs targeting liver, ocular, and neuromuscular tissues while also advancing ex vivo edited hematopoietic and immune cell therapies. They develop base and prime editing toolkits, apply CRISPRi/CRISPRa to modulate gene expression, and engineer AAV and lipid nanoparticle delivery for precise tissue tropism. Capabilities include GMP vector and cell manufacturing, computational off‑target profiling with potency assays, and translational tools such as companion diagnostics and biomarker-driven patient selection.
They primarily serve large pharmaceutical companies seeking platform licensing or co-development, specialty biotech developers expanding modality portfolios, and academic medical centers conducting early-stage trials. Outcomes include accelerated pipeline timelines through validated editing and delivery, de-risked clinical execution via GMP manufacturing and analytics, differentiated IP positions in gene-editing modalities, and the potential for functional cures that reduce long-term treatment costs and improve patient outcomes.
2. Buyers in the Biopharma CRISPR Gene Therapies sector
2.1 Top strategic acquirers of Biopharma CRISPR Gene Therapies companies
Beam Therapeutics
- Description: Provider of precision genetic medicines leveraging proprietary base and prime editing technologies to correct disease-causing mutations; developing a pipeline for serious genetic disorders, including sickle cell disease, beta-thalassemia and liver conditions, with candidates such as BEAM-101, BEAM-302, BEAM-301 and the ESCAPE non-chemotherapy conditioning platform.
- Key Products:
- BEAM-101: Ex vivo base-edited autologous stem-cell therapy for sickle cell disease, inducing fetal hemoglobin and showing robust HbF increases and hematologic normalization in Phase 1/2 BEACON data
- BEAM-302: Lipid-nanoparticle delivered base-editing treatment for alpha-1 antitrypsin deficiency, aiming for one-time correction of both lung and liver manifestations with first patient data targeted for 2025
- ESCAPE Technology: Antibody-based non-chemotherapy conditioning platform enabling safer hematopoietic stem-cell transplantation, validated by non-human primate studies to avoid busulfan toxicity
- BEAM-301: In vivo base-editing candidate for glycogen storage disease 1a, received IND clearance with initial patient dosing expected early 2025 to achieve durable metabolic correction.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Biopharma CRISPR Gene Therapies sector
M&A buyer group 1: Gene Editing
Beam Therapeutics
- Type: N/A
- Employees: ●●●●●
- Description: Provider of precision genetic medicines leveraging proprietary base and prime editing technologies to correct disease-causing mutations; developing a pipeline for serious genetic disorders, including sickle cell disease, beta-thalassemia and liver conditions, with candidates such as BEAM-101, BEAM-302, BEAM-301 and the ESCAPE non-chemotherapy conditioning platform.
- Key Products:
- BEAM-101: Ex vivo base-edited autologous stem-cell therapy for sickle cell disease, inducing fetal hemoglobin and showing robust HbF increases and hematologic normalization in Phase 1/2 BEACON data
- BEAM-302: Lipid-nanoparticle delivered base-editing treatment for alpha-1 antitrypsin deficiency, aiming for one-time correction of both lung and liver manifestations with first patient data targeted for 2025
- ESCAPE Technology: Antibody-based non-chemotherapy conditioning platform enabling safer hematopoietic stem-cell transplantation, validated by non-human primate studies to avoid busulfan toxicity
- BEAM-301: In vivo base-editing candidate for glycogen storage disease 1a, received IND clearance with initial patient dosing expected early 2025 to achieve durable metabolic correction.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Biopharma CRISPR Gene Therapies sector
3.1 - Buyout funds in the Biopharma CRISPR Gene Therapies sector
2.2 - Strategic buyer groups for Biopharma CRISPR Gene Therapies sector
4 - Top valuation comps for Biopharma CRISPR Gene Therapies companies
4.2 - Public trading comparable groups for Biopharma CRISPR Gene Therapies sector
Valuation benchmark group 1: Cell and Gene Therapy Biopharma Companies
Novartis
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and treatments, focusing on the research, development, manufacturing, and marketing of patented pharmaceuticals in areas such as oncology, immunology, cardiovascular, ophthalmology, and neuroscience to improve and extend lives worldwide.
- Key Products:
- Oncology Treatments: Medications for various types of cancer
- Immunology Drugs: Treatments for autoimmune and inflammatory diseases
- Cardiovascular Medicines: Drugs for heart and vascular conditions
- Neuroscience Therapies: Pharmaceuticals for neurological and psychiatric disorders
- Ophthalmology Solutions: Treatments for eye diseases and conditions